Successful treatment of severe allergic asthma with omalizumab in a girl with DiGeorge syndrome.
DiGeorge syndrome
immune dysregulation
immunodeficiency
omalizumab
severe allergic asthma
Journal
Central-European journal of immunology
ISSN: 1426-3912
Titre abrégé: Cent Eur J Immunol
Pays: Poland
ID NLM: 9702239
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
04
2018
accepted:
17
08
2018
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
14
1
2021
Statut:
ppublish
Résumé
DiGeorge syndrome (DGS) is a primary immunodeficiency disease characterized by multiple clinical features, including congenital heart defects, typical facial appearance, hypocalcemia, and immunodeficiency associated to thymic hypoplasia. A subset of patients with DGS may also have contemporary allergic diseases, possibly in the context of T cell dysregulation. Our work presents an unusual case of DGS in coincidence with severe allergic asthma successfully treated by humanized monoclonal anti-IgE antibody, omalizumab. Biological therapy with omalizumab is indicated as an add-on treatment for poorly controlled asthma in patients with severe persistent allergic asthma aged 6 years and above, who meet strict criteria. While data available from clinical trials suggest that omalizumab is generally well-tolerated, a little is known about its efficacy and tolerability in the context of underlying immunodeficiency. We reported for the first time that omalizumab could be safely effective in treatment of severe allergic asthma in patients with DGS, without modification of immunological parameters.
Identifiants
pubmed: 33437191
doi: 10.5114/ceji.2020.101269
pii: 42555
pmc: PMC7790012
doi:
Types de publication
Case Reports
Langues
eng
Pagination
361-363Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pediatr Allergy Immunol. 2005 May;16(3):226-30
pubmed: 15853951
Clinics (Sao Paulo). 2010;65(9):865-9
pubmed: 21049214
Eur Ann Allergy Clin Immunol. 2017 Mar;49(2):88-91
pubmed: 28294590
J Investig Allergol Clin Immunol. 2013;23(2):76-88; quiz 1 p. follow 88
pubmed: 23654073
Clin Immunol. 2010 Sep;136(3):409-18
pubmed: 20472505
Blood. 2004 Feb 1;103(3):1020-5
pubmed: 14525774
Respir Med. 2009 Aug;103(8):1098-113
pubmed: 19362459
Pediatr Allergy Immunol. 2015 Sep;26(6):551-6
pubmed: 25963882
J Allergy Clin Immunol. 2004 Apr;113(4):734-41
pubmed: 15100681
Cent Eur J Immunol. 2017;42(4):412-417
pubmed: 29472823
Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559
pubmed: 24414989